Meeting
2022 ASCO Genitourinary Cancers Symposium
Radiation technique and outcomes following moderately hypofractionated treatment of low risk prostate cancer: A secondary analysis of the NRG oncology RTOG 0415 randomized clinical trial.
Authors
David James Carpenter
Duke University Medical Center, Durham, NC
David James Carpenter , Joseph Kamel Salama , W. Robert Lee , Matthew J Boyer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 243)
DOI
10.1200/JCO.2022.40.6_suppl.243
Abstract #
243
Poster Bd #
L1
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Long-term clinical and toxicity outcomes of hypofractionated intensity-modulated radiation therapy for clinically localized prostate cancer.
First Author: Rupesh Kotecha
Poster
2020 Genitourinary Cancers Symposium
Eight-year outcomes of a phase III randomized trial of conventional versus hypofractionated high-dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): Update from the CHHiP Trial.
First Author: David P. Dearnaley
Poster
2019 Genitourinary Cancers Symposium
Moderately hypofractionated radiotherapy for localized prostate cancer: Long-term outcomes for 854 consecutive patients treated over 10 years (70 Gy in 2.5 Gy/fraction).
First Author: Omar Y. Mian
Poster
2023 ASCO Annual Meeting
RT-PACE: Phase I/II study of adjuvant whole pelvic hypofractionated radiotherapy for non-metastatic cervical and endometrial cancer.
First Author: Christina H. Son